Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,321 papers from all fields of science
Search
Sign In
Create Free Account
Anti-ErbB3 Monoclonal Antibody KTN3379
Known as:
KTN3379
A monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Anti-ErbB3…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted…
G. Falchook
,
T. Bauer
,
+4 authors
J. Eder
2016
Corpus ID: 80243179
2501Background: KTN3379 is a fully human anti-ErbB3 antibody with YTE half-life extension engineering that uniquely binds domain…
Expand
2016
2016
Abstract 1196: Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN
G. Ligon
,
J. Lillquist
,
+5 authors
Diego Alvarado
2016
Corpus ID: 78315279
ErbB3, the kinase-dead member of the EGFR/ErbB family, has been implicated as an oncogenic driver in a number of solid tumor…
Expand
2016
2016
Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer
T. Brand
,
S. Hartmann
,
+6 authors
J. Grandis
2016
Corpus ID: 79185466
Background: Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with a rising incidence of more than 600,000…
Expand
2016
2016
Abstract 3053: Inhibition of heregulin-mediated ErbB3 signaling as a radiosensitization therapy for head and neck cancers
M. Baro
,
J. Balart
,
J. Contessa
2016
Corpus ID: 79302406
PURPOSE: EGFR signaling confers resistance to radiation therapy (RT) and is a validated target in head and neck squamous cell…
Expand
2016
2016
Abstract 2979: Dual targeting of HER3 and PIK3CA has potent anti-tumor effects in pre-clinical models of HNSCC
N. Khan
,
K. Davis
,
+6 authors
U. Duvvuri
2016
Corpus ID: 78686918
Background: The phosphoinositide 3-kinase (PI3K) pathway is a frequently mutated oncogenic pathway in head and neck squamous cell…
Expand
2015
2015
A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.
T. Bauer
,
J. Infante
,
+5 authors
G. Falchook
2015
Corpus ID: 79602618
2598 Background: KTN3379 is a human monoclonal antibody against a unique epitope of human epidermal growth factor receptor-3…
Expand
2015
2015
Abstract 2615: Dual ErbB blockade with KTN3379 and cetuximab yields enhanced antitumor activity by inhibiting parallel signaling pathways in SCCHN
Diego Alvarado
,
S. Seibel
,
+4 authors
T. Lavallee
2015
Corpus ID: 78650206
2015
2015
Abstract 1672: Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379
Diego Alvarado
,
Sangwon Lee
,
+5 authors
J. Schlessinger
2015
Corpus ID: 73887015
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA ErbB3 signaling plays an important role in the…
Expand
2014
2014
407 Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379
Diego Alvarado
,
Sangwon Lee
,
+6 authors
J. Schlessinger
2014
Corpus ID: 73240993
2014
2014
210 A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancers
P. LoRusso
,
T. Lavallee
,
L. Kimmel
,
C. Lubeski
,
R. Gedrich
,
C. Sidor
2014
Corpus ID: 74847899
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE